secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001193125-26-054787
Event type: regulatory
Sentiment:  negative
Materiality: 0.55
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo Biopharma receives Nasdaq bid price deficiency notice; compliance period through Aug 2026
--------------------------------------------------------------------------------

- Received letter on Feb 17, 2026 re: ADS closing bid price below $1.00 for 30 consecutive business days.
- 180-day compliance period until August 17, 2026 to regain minimum bid price requirement.
- To regain compliance, bid price must close at $1.00+ for at least 10 consecutive business days.
- If not compliant by Aug 17, may be eligible for additional 180-day grace period subject to other Nasdaq standards.
- ADSs continue trading under MREO; company states business operations unaffected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000119312526054787/0001193125-26-054787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000119312526054787/mreo-20260217.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-054787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer